InstalabLoading...
InstalabLoading...
A normal total IgG (immunoglobulin G) result on a standard blood panel can hide a specific weakness underneath. IgG1 makes up roughly 60 to 70 percent of all the IgG in your blood, and when it runs low, your ability to fight off bacterial and viral infections drops, even if the total number looks fine.
Measuring IgG1 separately tells you whether the largest workhorse of your antibody defense is actually pulling its weight. It is especially useful if you deal with repeated respiratory infections, have an autoimmune condition, or want to understand how your immune system is holding up as you age.
IgG1 (immunoglobulin G subclass 1) is one of four subtypes of IgG, the main antibody circulating in your blood. Your immune system's B cells (white blood cells that specialize in making antibodies) produce IgG1 primarily in response to proteins from viruses and bacteria. Once made, IgG1 antibodies can tag invaders for destruction, activate a cascade of immune proteins called complement that punch holes in bacterial membranes, and help immune cells like natural killer cells identify and kill infected or abnormal cells by guiding those cells directly to the target.
IgG1 is also the subclass that crosses the placenta most efficiently, making it the primary source of antibody protection for newborns during the first weeks of life. Long-lived antibody-producing cells in your bone marrow keep making the same IgG1 antibodies for years, which is why immunity from vaccines and past infections can persist for a long time.
The strongest outcome data for IgG1 come from people with COPD (chronic obstructive pulmonary disease, a condition where the lungs are chronically inflamed and damaged). In a study of 489 hospitalized COPD patients, those with IgG1 deficiency had a significantly higher risk of dying within one year compared to those with normal IgG1 levels. IgG4 deficiency carried a similar mortality risk, while IgG2 and IgG3 deficiency did not.
A larger analysis from the SPIROMICS study, which followed about 1,500 adults with or at risk for COPD, found that lower IgG1 and IgG2 levels were independently associated with more severe flare-ups, even after accounting for other risk factors. A separate study confirmed that reduced IgG1 is an independent risk factor for COPD exacerbations and showed it also predicts hospitalizations.
If you have COPD or get frequent respiratory infections, a low IgG1 result is a signal worth acting on. It may explain why infections keep coming back and could point toward preventive strategies like immunoglobulin replacement therapy or closer surveillance.
In critically ill patients, immunoglobulin levels matter as a prognostic signal. A study of 278 sepsis patients found that low levels of total IgG, IgA (immunoglobulin A), and IgM (immunoglobulin M), rather than IgG1 specifically, consistently predicted both acute and post-acute mortality, with the protective association being strongest in patients with moderate organ failure. Because IgG1 makes up the majority of total IgG, it is likely a major contributor to that signal, but the study did not break results down by IgG subclass. In COVID-19 specifically, a study of 62 critically ill patients found that total IgG deficiency was common and associated with worse disease severity and increased odds of death, again supporting the idea that low overall antibody levels, which IgG1 dominates, carry clinical risk.
IgG1 is not only a defender. When the immune system misfires, IgG1 autoantibodies (antibodies directed against your own tissues) are often the dominant culprits. In MOG antibody associated disease, a group of conditions involving inflammation of the brain's protective nerve coatings, IgG1 is the predominant antibody subclass. A multicenter study of 454 patients confirmed that IgG1-based assays detect cases that broader total IgG assays can miss.
A separate condition defined by IgG1 antibodies targeting a nerve protein called neurofascin causes a severe, rapidly progressive neuropathy with high mortality. Identifying the IgG1 subclass in these cases matters because it changes treatment decisions, pointing toward aggressive immunotherapy.
IgG subclass deficiency (IgGSD) and common variable immunodeficiency (CVID) are two conditions that cause recurrent infections, but they differ in severity and management. A retrospective study of 366 patients found that IgGSD has distinct clinical features compared to CVID, and the two require different follow-up strategies. Measuring IgG1 alongside the other subclasses helps your clinician distinguish between these diagnoses and plan appropriate care.
IgG1 reference ranges depend heavily on your age, sex, race, and the lab method used. A study of over 12,750 patients in a U.S. health system found that Asian and Black individuals had higher mean IgG1 levels than White individuals, and that non-White patients were more often flagged as having results above the upper limit of normal. Applying one set of cutpoints to all populations risks mislabeling healthy variation as pathology.
These adult reference intervals come from a study of 636 healthy Chinese adults measured by immunonephelometry (a light-scattering technique labs use to measure antibody concentration). They provide orientation, but your own lab's reported range should be your primary reference.
| Category | IgG1 Range (g/L) | What It Suggests |
|---|---|---|
| Low | Below 3.82 | Possible IgG1 deficiency; increased infection susceptibility |
| Normal | 3.82 to 9.29 | Typical immune function for this subclass |
| High | Above 9.29 | May reflect chronic immune activation, infection, or autoimmune activity |
IgG1 levels rise from infancy through childhood and generally reach adult levels around puberty. In children, age-specific reference ranges are essential because a level that is normal for a teenager would be high for a toddler. Always compare your results within the same lab over time for the most meaningful trend.
A systematic review and meta-analysis of determinants of serum immunoglobulin levels confirmed that age, sex, ethnicity, diet, lifestyle, and cardiometabolic factors all influence immunoglobulin concentrations. Older age tends to shift the subclass balance, and children's IgG1 levels follow the same general trajectory as total IgG: a dip in the first few months of life as maternal antibodies clear, then a gradual climb through childhood.
A study of 910 healthy Black and White children found that young Black children had lower IgG1, IgG2, and IgG4 concentrations than White children, raising the concern that some may be erroneously classified as IgG subclass deficient when using reference ranges derived from predominantly White populations.
The biggest source of error in IgG1 testing is the assay itself. Standard immunonephelometric assays can show cross-reactivity between subclasses. When IgG4 is very high (as in IgG4-related disease), the reported IgG1 value may be artificially elevated because the assay's antibodies partly pick up IgG4. A specialized technique called LC-MS/MS (liquid chromatography-mass spectrometry) resolves this discrepancy and is the more accurate method in that setting.
Acute infections, chronic inflammation, and critical illness can all temporarily shift IgG1 levels. In hospitalized COVID-19 patients, IgG1 levels reflected disease severity, with sicker patients showing different patterns than those with mild disease. Drawing IgG1 during an acute illness will give you a snapshot of your immune response to that illness, not your baseline immune status. Wait at least several weeks after recovery before testing for baseline assessment.
A single IgG1 measurement gives you a snapshot, but the real value comes from tracking your number over time. IgG1 can fluctuate with infections, immune challenges, and seasonal changes in pathogen exposure. If you are investigating possible immune deficiency, a single low reading should always be confirmed with a repeat test at least four to six weeks later, drawn when you are feeling well.
For ongoing monitoring, test at least annually. If you are making changes intended to support immune function or are being treated for an immune deficiency, retest every three to six months to see whether your levels are responding. Always use the same lab, because different assay platforms can give different absolute numbers for the same sample.
A low IgG1 result, confirmed on repeat testing when you are healthy, warrants a full IgG subclass panel (IgG1 through IgG4) along with total IgG, IgA, and IgM. This combination helps distinguish isolated IgG1 deficiency from broader conditions like CVID. If subclass deficiency is confirmed, a referral to an immunologist is the next step. They may order vaccine challenge tests (measuring whether your immune system can mount a normal antibody response to a vaccine) to determine how clinically significant the deficiency is.
A high IgG1 result, especially if persistent, suggests your immune system is chronically activated. The next question is why. Consider ordering inflammatory markers like CRP (C-reactive protein) and ESR (erythrocyte sedimentation rate, a measure of how quickly red blood cells settle in a test tube), and discuss with your clinician whether autoimmune testing or infection workup is appropriate. In the context of liver disease, elevated IgG1 has been associated with higher infection risk and worse outcomes, so liver function tests are relevant companions.
Evidence-backed interventions that affect your IgG1 level
IgG1 is best interpreted alongside these tests.